Fixing common blood disorder would make kidney transplants more successful

Correcting anemia, a red blood cell deficiency, can preserve kidney function in many kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results indicate that aggressively treating anemia may help save the kidneys—and possibly the lives—of many transplant recipients.

Anemia commonly arises in patients with disease because the kidneys secrete most of the hormone erythropoietin that stimulates production. is also a common complication of kidney transplantation, with a prevalence of 25% to 40% after the first year.

Gabriel Choukroun, MD, PhD (CHU Amiens in France) and his colleagues initiated the Correction of Anemia and PRogression of Renal Insufficiency in Transplant patients (CAPRIT) study to see if the drug epoetin beta (a synthetic form of erythropoietin) could help preserve in kidney transplant recipients with anemia. Specifically, the investigators tested whether completely correcting anemia (by normalizing levels of hemoglobin, a blood component that carries oxygen) is better than partially correcting anemia.

During the study, 63 kidney transplant recipients took epoetin beta so that their hemoglobin levels remained in the normal range of 13.0 to 15.0 g/dL, while 62 patients took epoetin beta so that their hemoglobin levels hovered at a lower concentration of 10.5 to 11.5 g/dL.

Among the major findings after patients were treated for two years:

  • 4.8% of patients with completely corrected anemia developed kidney failure, compared with 21% of patients with partially corrected anemia.
  • 94.6% of transplanted kidneys in patients with completely corrected anemia were functional, compared with 80% in patients with partially corrected anemia.
  • Patients with completely corrected anemia experienced a significant improvement in quality of life at six and 12 months after starting therapy.
"This study shows that correction of anemia in with anemia slows the progression of kidney failure and improves survival of transplanted kidneys," said Dr. Choukroun. Additional studies are needed to determine whether this also prolongs patients' lives.

More information: The article, entitled "Correction of Post-Kidney Transplant Anemia Reduces Progression of Allograft Nephropathy," will appear online on December 22, 2011, doi: 10.1681/ASN.2011060546

add to favorites email to friend print save as pdf

Related Stories

New approach may help dialysis patients fight anemia

Nov 29, 2010

A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patients—possibly offering a new approach to treatment of kidney disease-related anemia, according to a study appearing ...

Recommended for you

New approach to particle therapy dosimetry

Dec 19, 2014

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

ironjustice
not rated yet Dec 23, 2011
Isn't it amazing that the same hemoglobin which KILLS kidney disease patients, 12.5 , at an even HIGHER number RESCUES kidney transplant patients? One might wonder whether there are any 'conflicts of interest' here. Pharmaceutical companies which supply this very expensive drug erythropoietin ? Erythropoietin USED to be the 'apple of everyones eye' BUT when it was discovered it was killing everyone it went from ten to one in sales.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.